Currently, there are three PD-L1 inhibitors and two PD-1 inhibitors approved by the Food and Drug Administration for the treatment of bladder cancer (Atezolizumab, Avelumab, Durvalumab, Nivolumab, Pembrolizumab, and Ipilimumab). This evidence concerns the gene CD274 and urinary bladder cancer.